![](/rp/kFAqShRrnkQMbH6NYLBYoJ3lq9s.png)
Rani Therapeutics – Rani Therapeutics has developed a …
The Rani platform is capable of delivering orally any payload, including proteins, peptides, and antibodies, to which could help millions of patients fight their disease in a wide range of …
Rani Therapeutics Announces Preclinical Data Demonstrating …
6 days ago · Rani Therapeutics is a clinical-stage biotherapeutics company focused on advancing technologies to enable the development of orally administered biologics and drugs. Rani has …
Rani Therapeutics Announces Preclinical Data Demonstrating …
6 days ago · Rani Therapeutics is a clinical-stage biotherapeutics company focused on advancing technologies to enable the development of orally administered biologics and drugs.
Rani Therapeutics Announces Preclinical Data ... - Morningstar
Feb 5, 2025 · Rani Therapeutics is a clinical-stage biotherapeutics company focused on advancing technologies to enable the development of orally administered biologics and drugs.
Rani Therapeutics Holdings, Inc. (RANI) - Yahoo Finance
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the …
Investor Relations - Rani Therapeutics, LLC
Rani is a clinical stage biotherapeutics company advancing technologies to enable the development of orally administered biologics, which we believe will have the potential to …
Pipeline – Rani Therapeutics
RT-105 is the original RaniPill capsule containing a TNF-α inhibitor antibody for the treatment of psoriatic arthritis. Several TNF-alpha antibodies, such as adalimumab, have been approved by …
Our Technology – Rani Therapeutics
Rani Therapeutics has developed a disruptive technology for the oral delivery of biologics. The RaniPill® Capsule is an innovative robotic pill that moves fully intact through the stomach, …
Rani Therapeutics Announces Partnership with ProGen on …
Jun 24, 2024 · Rani has developed the RaniPill® capsule, which is a novel, proprietary and patented platform technology, intended to replace subcutaneous injection or intravenous …
Rani Therapeutics reports positive obesity treatment study - MSN
Rani Therapeutics also announced its anticipation for a Phase 1 clinical trial in 2025 for RT-114, an oral GLP-1/GLP-2 dual agonist for obesity treatment, developed in partnership with ProGen.